Patents Issued in August 1, 2017
  • Anti-inflammatory compounds
    Patent number: 9717718
    Abstract: Compositions comprising isolated ido-BR1 are described for use in therapy or prophylaxis, including the treatment of inflammatory diseases (for example as anti-inflammatory drugs) and to reduce inflammation. Also described are methods for monitoring the quality of a Cucurbitaceae extract, to processes for producing a Cucurbitaceae extract as well as to Cucurbitaceae extracts obtainable by such processes.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: August 1, 2017
    Assignee: Phytoquest Limited
    Inventor: Robert James Nash
  • Treatment, prevention, and reversal of alcohol-induced liver disease
    Patent number: 9717719
    Abstract: This invention relates to methods for treating, preventing, or reversing liver disease or damage produced by chronic alcohol intake by administering at least one peroxisome proliferator activated receptor (PPAR) agonist.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: August 1, 2017
    Assignee: Rhode Island Hospital
    Inventors: Suzanne Marie de la Monte, Jack Raymond Wands
  • Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
    Patent number: 9717720
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: August 1, 2017
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
    Patent number: 9717721
    Abstract: Aryl-quinolin derivatives for use in inhibiting vasculogenic mimicry, treating diseases characterized by abnormal vascular morphology or function and/or by the presence of vasculogenic mimicry in a subject in need thereof are disclosed. In one embodiment of the invention, the compounds are for use in treating metastatic tumor, hyperproliferative, or angiogenic diseases. In another embodiment of the invention, the compound for use may combine an additional therapeutic agent such as anti-cancer agents, anti-inflammatory agents, anti-proliferative agents, anti-hormonal agents, or any combination thereof for use.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: August 1, 2017
    Assignee: TAIRX, INC.
    Inventors: Yi-Wen Chu, Du-Shieng Chien
  • Methods and agents for treating tyrosinase-positive albinism
    Patent number: 9717722
    Abstract: Methods for treating a subject with tyrosinase-positive albinism; agents and compositions thereof for use in treating tyrosinase-positive albinism; and medicaments for treating tyrosinase-positive albinism are described herein. Such methods; agents and compositions thereof; and medicaments relate to chloroquine or rapamycin or compositions thereof and may further relate to nitisinone used in conjunction with the chloroquine or rapamycin or a composition of either of which.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: August 1, 2017
    Assignee: New York University
    Inventors: Seth J. Orlow, Prashiela Manga
  • Liposomes useful for drug delivery
    Patent number: 9717723
    Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: August 1, 2017
    Assignee: IPSEN BIOPHARM LTD.
    Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
  • Methods for treating pancreatic cancer using combination therapies
    Patent number: 9717724
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: August 1, 2017
    Assignee: Ipsen Biopharm Ltd.
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Use of opioid antagonists
    Patent number: 9717725
    Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: August 1, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia
  • Product and method for treating diarrhea
    Patent number: 9717726
    Abstract: A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 1, 2017
    Assignee: Maregade RX, LLC
    Inventor: Reed B Hogan, II
  • Methods of treating and preventing leukemia and other cancers of the blood and bone
    Patent number: 9717727
    Abstract: The present invention relates to preventing and treating leukemia and other cancers of the blood and bone, as well as disorders of the blood, by inhibiting gut-derived serotonin. The inhibition of the gut-derived serotonin is accomplished by inhibiting Tph1, an enzyme responsible for the production of gut-derived serotonin. The present invention also relates to preventing and treating leukemia and other cancers of the blood and bone, as well as disorders of the blood, by increasing the number, growth and proliferation of osteoblasts.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 1, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Stavroula Kousteni
  • Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
    Patent number: 9717728
    Abstract: A pharmaceutical combination comprising (a) a B-Raf inhibitor and (b) a histone deacetylase inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: August 1, 2017
    Assignee: Novartis AG
    Inventors: Stuart John Gallagher, Peter Hersey
  • Fluorinated integrin antagonists
    Patent number: 9717729
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 1, 2017
    Assignee: SciFluor Life Sciences, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 9717730
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 1, 2017
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • TEC family kinase inhibitor adjuvant therapy
    Patent number: 9717731
    Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: August 1, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Tarak D. Mody, John C. Byrd, Betty Y. Chang, Jason A. Dubovsky, Natarajan Muthusamy, Amy Jo Johnson
  • Drug combination
    Patent number: 9717732
    Abstract: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a ?2-adrenergic receptor agonist.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: August 1, 2017
    Assignee: VERONA PHARMA PLC
    Inventors: Michael J. A. Walker, Mario Cazzola, Luigino Calzetta
  • Edible plant-derived microvesicle compositions including conjugated therapeutic agents and methods for using the same
    Patent number: 9717733
    Abstract: A composition is provided that includes a microvesicle derived from an edible plant and a therapeutic agent conjugated to the microvesicle. The therapeutic agent can be chemically-linked to a plasma membrane of the microvesicle with a cross-linking agent and the edible plant can be a fruit or a vegetable. Methods for treating an inflammatory disorder or a cancer are further provided and include administering to a subject in need thereof an effective amount of a composition including a microvesicle derived from an edible plant and having a therapeutic agent conjugated to the microvesicle.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: August 1, 2017
    Assignee: University of Louisville Research Foundation, Inc.
    Inventor: Huang-Ge Zhang
  • Chewable lipid supplements containing caffeine for increasing alertness, focus and energy
    Patent number: 9717734
    Abstract: Flavored chewable wafers containing caffeine suitable for increasing alertness and allow an individual to perform tasks in a more focused and energetic manner comprises, formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: August 1, 2017
    Assignee: ALLERGY RESEARCH GROUP, LLC
    Inventor: Robert Settineri
  • Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
    Patent number: 9717735
    Abstract: This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: August 1, 2017
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Ricky D. Gaston, Robert C. Gadwood
  • Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
    Patent number: 9717736
    Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: August 1, 2017
    Assignee: Kudos Pharmaceuticals Limited
    Inventors: Heather Mary Ellen Duggan, Frederic Georges Marie Leroux, Karine Fabienne Malagu, Niall Morrison Barr Martin, Keith Menear, Graeme Cameron Murray Smith
  • Vacuolin-1 as an inhibitor of autophagy and endosomal trafficking and the use thereof for inhibiting tumor progression
    Patent number: 9717737
    Abstract: Methods of treating autophagy related diseases, e.g. cancer and malaria, using novel autophagy inhibiting agents are described.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: August 1, 2017
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Jianbo Yue, Yingying Lu
  • Aerosol fluoroquinolone formulations for improved pharmacokinetics
    Patent number: 9717738
    Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 1, 2017
    Assignee: Horizon Orphan LLC
    Inventors: David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
  • 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
    Patent number: 9717739
    Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 1, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
  • Treatment of adrenal insufficiency
    Patent number: 9717740
    Abstract: The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to pediatric treatment regimens, the treatment of the elderly and non-human animals.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: August 1, 2017
    Assignee: Diurnal Limited
    Inventors: Hiep Huatan, Richard Ross, Martin Whitaker
  • Method and compositions for treating psoriasis
    Patent number: 9717741
    Abstract: Method and composition for treating psoriasis and other skin disorders.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: August 1, 2017
    Assignee: ANAPLASI PHARMACEUTICALS LLC
    Inventor: Edward Richard Yuhas
  • Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
    Patent number: 9717742
    Abstract: This invention relates, e.g., to a synthetic compound, Oxy133, having the structure [Formula I] or a bioactive or pharmaceutical composition comprising Oxy133 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 1, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Farhad Parhami, Michael E. Jung, Frank Stappenbeck
  • Pharmaceutical compositions and methods of use of 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 9717743
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: August 1, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • Use of 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to prevent secondary hyperparathyroidism or the symptoms thereof
    Patent number: 9717744
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 1, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
    Patent number: 9717745
    Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: August 1, 2017
    Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.
    Inventor: Wei He
  • Use of edelfosine and other synthetic ether alkyl-lysophospholipids (APLs) for seizures and related diseases
    Patent number: 9717746
    Abstract: Synthetic ether alkyl-lysophospholipids (APLs) provide an effective treatment for subjects suffering from cholinergic seizures. Among other uses, APLs may be used to treat the effects of epileptic seizures in particular cholinergic seizures caused by exposure to insecticides or chemical warfare nerve agent exposure. Edelfosine, an APL, has been show to be particularly effective in these areas.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: August 1, 2017
    Inventor: Peter Andrew Ferchmin
  • Osteoclast inhibitors for knee conditions
    Patent number: 9717747
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 1, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Compositions and methods for treating an infection
    Patent number: 9717748
    Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. The present application also relates to anti-infective agents and methods of using anti-infective agents. For example, disclosed herein are compounded compositions comprising an anti-bacterial agent, an anti-fungal agent, and an excipient base and methods of using a compounded composition to treat or prevent a bacterial infection, a fungal infection, or both, or a suspected bacterial infection, a suspected fungal infection, or both. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 1, 2017
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Production of stable non-polyadenylated RNAs
    Patent number: 9717749
    Abstract: The invention relates in aspects to hybrid RNAs lacking a poly-A tail and nucleic acid vectors for expressing the RNA. The hybrid RNAs in some instances have a 3? terminal stabilizing triple helical structure. Related methods for expressing said RNAs in vivo and in vitro are also disclosed.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: August 1, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Jeremy E. Wilusz, Phillip A. Sharp
  • Compositions and methods for modulation of SMN2 splicing in a subject
    Patent number: 9717750
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: August 1, 2017
    Assignees: Biogen MA Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
  • Chitin or derivatives thereof for the prevention and/or treatment of parasitoses
    Patent number: 9717751
    Abstract: The subject matter of the present invention is the use of chitin or a derivative of chitin for preventing and/or treating parasitoses, and in particular cryptosporidiosis. The present invention also pertains to a composition that comprises at least one base agent chosen from among chitin or a derivative of chitin and at least one secondary agent chosen from among an agent for stimulating immunity and an antiparasite agent, as well as the use of same for preventing and/or treating parasitoses, in particular cryptosporidiosis.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 1, 2017
    Assignee: LESAFFRE ET COMPAGNIE
    Inventors: Eric Auclair, Jean-Philippe Marden, Fabrice Laurent, Sonia Lacroix-Lamande
  • Uses of antagonists of hyaluronan signaling
    Patent number: 9717752
    Abstract: Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: August 1, 2017
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Duke University, The University of North Carolina at Chapel Hill
    Inventors: Stavros Garantziotis, John W. Hollingsworth, Bryan P. Toole, Jian Liu
  • Method for reducing artificial joint reductions
    Patent number: 9717753
    Abstract: The present invention provides a lubricating composition comprising an alginic acid or a salt or ester thereof, which is effective in reducing frictions in artificial joints and wear of artificial joint implants. Also provided is a method for lubricating artificial joints comprising administering said composition to a synovial cavity of a subject. In another aspect, the present invention provides use of an alginic acid or a salt or ester thereof in manufacturing a lubricating composition.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 1, 2017
    Assignee: National Taipei University of Technology
    Inventors: Hsu-Wei Fang, Shu-Wen Chen, Yi-Ling Huang
  • Glucocerebroside treatment of disease
    Patent number: 9717754
    Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: August 1, 2017
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
  • Method of treating inflammation
    Patent number: 9717755
    Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: August 1, 2017
    Assignee: Cytosorbents Corporation
    Inventors: Phillip P. Chan, Wei-Tai Young, Vincent J. Capponi, Thomas D. Golobish, Robert H. Bartlett, Humayra Begum Ali
  • Method of treating traumatic brain or spinal cord injury with biomembrane sealing agent and magnesium compounds
    Patent number: 9717756
    Abstract: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 1, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, William F. McKay, Jeffrey C. Marx
  • Composition and method to treat and prevent muscle cramping
    Patent number: 9717757
    Abstract: A method of treating muscle cramps and muscle pain, and to relieve swelling in and around muscles after strenuous physical activity is provided, whereby an aqueous composition is applied topically to the skin overlying the affected muscles, the composition has dissolved, suspended or dispersed therein (a) an anti-inflammatory agent; (b) an agent that stimulates or promotes cell growth; and (c) an agent that enhances or stimulates the skin's immune system, wherein components (a), (b) and (c) are different.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: August 1, 2017
    Inventor: Samuel N. Gasque, Jr.
  • High-affinity DMF5 T cell receptor (TCR) variants
    Patent number: 9717758
    Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: August 1, 2017
    Assignees: University of Massachusetts, University of Notre Dame du Lac
    Inventors: Brian G. Pierce, Zhiping Weng, Brian M. Baker
  • Modification of CXCR4 using engineered zinc finger proteins
    Patent number: 9717759
    Abstract: Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and cells comprising polynucleotides encoding ZF-TFs or ZFNs and/or cells comprising ZF-TF or ZFNs are also provided.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 1, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Jeffrey C. Miller, Jianbin Wang
  • Microvesicles (MVS) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
    Patent number: 9717760
    Abstract: The invention is in the field of therapeutic treatment of tumors. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumor effect when administered to a patient affected by a tumor disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: August 1, 2017
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Stefania Bruno, Maria Beatriz Herrera Sanchez, Valentina Fonsato, Giovanni Camussi, Ciro Tetta
  • Stem cell-derived neural cells for cell therapy in neurological disorders
    Patent number: 9717761
    Abstract: The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: August 1, 2017
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Sandu Pitaru, Javier Ganz, Daniel Offen, Eldad Melamed
  • Compositions of cardiomyocyte subpopulations
    Patent number: 9717762
    Abstract: The present invention provides the use of the antigens CD49e and/or CD49f as selection markers for enrichment, isolation, detection and/or analysis of atrial and ventricular cardiomyocytes and a method for enrichment, isolation, detection and/or analysis of these cells from a sample comprising cardiomyocytes. In addition substantially pure compositions of these cardiomyocyte subpopulations are provided.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: August 1, 2017
    Assignee: Miltenyi Biotec
    Inventors: Anne Maria Wiencierz, Dominik Eckardt, Andreas Bosio
  • Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
    Patent number: 9717763
    Abstract: Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: August 1, 2017
    Assignee: DEPUY SYNTHES PRODUCTS, INC.
    Inventors: Sanjay Mistry, Anthony J. Kihm, Ian R. Harris, Alexander M. Harmon, Darin J. Messina, Agnieszka Seyda, Chin-Feng Yi, Anna Gosiewska
  • Egg preparation with regenerating, analgesic and/or anti-inflammatory properties
    Patent number: 9717764
    Abstract: It comprises an egg preparation comprising a mixture of the yolk and the white extracted from a fertilized egg incubated for a period comprised between 18 hours and 36 hours, wherein the mixture of the yolk and white is in a ratio in which the amount of the white is comprised between 2% and 40% by volume of the yolk volume, useful as regenerating, analgesic and/or anti-inflammatory agent, as well as its preparation process. It also relates to functional foods, dietary supplements, and pharmaceutical or veterinary compositions containing the egg preparation. It also relates to cosmetic compositions comprising the egg preparation and to its use as skin care or hair or fur care agent.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: August 1, 2017
    Assignee: OVIVITY GROUP, S.L.
    Inventor: Juan Cunill Aixelà
  • Method of identifying a biologically-active composition from a biofilm
    Patent number: 9717765
    Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: August 1, 2017
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
    Patent number: 9717766
    Abstract: The present invention disclosed herein describes (i) the growth promotional activity of natural plant based fibres on Bacillus coagulans MTCC 5856; (ii) the combination of natural plant based fibres and Bacillus coagulans MTCC 5856 to inhibit Gram Negative pathogenic bacteria and (iii) the production of short chain fatty acids (SCFA) by Bacillus coagulans MTCC 5856 using plant based natural fibres.
    Type: Grant
    Filed: August 29, 2015
    Date of Patent: August 1, 2017
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
  • Compositions and methods for improving human health and nutrition
    Patent number: 9717767
    Abstract: The present invention provides compositions and methods of promoting human health and nutrition.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: August 1, 2017
    Assignee: BIOWISH Technologies, Inc.
    Inventors: Richard S. Carpenter, E. Wesley Huff, Amit Kapur